
A02 The feedback loop among miR-449b-3p/ADAM17/NF-κB promotes metastasis in nasopharyngeal carcinoma. Qian Fei, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

A03 Isolation, characterization and expansion of circulating tumor cells in head and neck cancers. Arutha Kulasinghe, The School of Biomedical Sciences, IHBI/QUT, Brisbane, QLD, Australia.

A04 Tumor development trajectories for exploring differences between cancer subtypes. Ignaty Leshchiner, Broad Institute of MIT and Harvard, Boston, MA, USA.

A05 CD44, total protein and p16 marker expression in oral rinses from oral and oropharyngeal cancer patients and controls. Drew Smith, FIU, Miami, FL, USA.

A06 Interrogation of HPV-positive oropharyngeal squamous cell carcinomas with RNA-based Nanostring assay demonstrates expression profile associated with treatment resistance. Paul Zolkind, Washington University School of Medicine, St. Louis, MO, USA.

A07 Improved prognosis of HPV-positive oropharyngeal cancers is associated with a suppression of TGF-β-mediated immune evasion. Pinaki Bose, University of Calgary, Calgary, AB, Canada.

A08 Resolving STING-mediated tumor immune microenvironment shift at single-cell resolution. Blake Heath, University of Michigan, Ann Arbor, MI, USA.

A09 Activation of the CD45 receptor on leukocytes by the C24D peptide results in immune mediated head and neck squamous cell carcinoma apoptosis. Aviram Mizrachi, Rabin Medical Center, Petah Tikva, Israel.

A10 Treatment of squamous cell carcinoma by alpha radiation-based brachytherapy (Alpha DaRT). Aviram Mizrachi, Rabin Medical Center, Petah Tikva, Israel.

A11 STAT1 mediates resistance to experimental oral cancer which is associated with enhanced anti-tumor T cell responses. Steve Oghumu, Ohio State University, Columbus, OH, USA.

A12 Metformin treatment in LAHNSCC induces an anti-tumorigenic immune response. Sarah Palackdharry, University of Cincinnati, Cincinnati, OH, USA.
A13 Neoadjuvant PD-1 mAb treatment induces post-operative immune memory responses against both immunodominant and immunorecessive antigens. Clint Allen, National Institutes of Health, Bethesda, MD, USA.

A14 The p53R172H gain-of-function mutation promotes resistance to oral cancer immunoprevention. Carlos Caulin, University of Arizona, Tucson, AZ, USA.

A15 Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors. Elizabeth Evans, Vaccinex, Rochester, NY, USA.

A16 Natural killer cell therapy efficacy is enhanced through inhibition of myeloid derived suppressor cell trafficking. Clint Allen, National Institutes of Health, Bethesda, MD, USA.

A17 Neutrophil-to-lymphocyte ratio predicts response to neoadjuvant presurgical PD-1 inhibition in oral cancer. Joshua Horton, Medical University of South Carolina, Charleston, SC, USA.

A18 Personalized RNA nanoparticles remodel the HNSCC immunologic milieu to unlock immunotherapeutic activity. Natalie Silver, University of Florida, Gainesville, FL, USA.

A19 Opioid prescriptions in the military defense system head and neck cancer population, FY2007 - FY2014. Art Ambrosio, Naval Medical Center San Diego, San Diego, CA, USA.

A20 Dysgeusia may play a role in negatively affecting mood and anxiety in post-radiation head and neck patients. Thomas Arnell, Larner College of Medicine at UVM, Burlington, VT, USA.

A21 Increasing use of adjuvant radiation for parathyroid carcinoma is associated with improved survival outcomes: A population-based study. Richard Cannon, University of Utah, Salt Lake City, UT, USA.

A22 Patient-derived organoids recapitulate response heterogeneity in head and neck cancer. Vincent Vui King Chong, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A23 Transoral robotic surgery for primary oncologic resection: Outcomes from a rural academic medical center. Eric Eisen, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
A24 Multitiered assessment of the incidence and demographics of patients with multiple human papillomavirus-mediated head and neck cancers. Daniel Faden, MEEI, Boston, MA, USA.

A25 Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Daria Gaykalova, Johns Hopkins University, Baltimore, MD, USA.

A26 Genomic and epigenomic analysis reveal a distinct and targetable transcriptional signature of HNSCC subtypes. Christian Gluck, Jacobs School of Medicine and Biomedical Science, University at Buffalo, Buffalo, NY, USA.

A27 Differential protein-interactome of MYB-NF1B fusion in adenoid cystic carcinoma. Patrick K. Ha, UCSF, San Francisco, CA, USA.

A28 Predictive factors for mortality after surgery alone for human papilloma virus associated oropharynx squamous cell carcinoma: Analysis of the National Cancer Database. Mary Han, School of Medicine, University of California-San Francisco, San Francisco, CA, USA.

A29 Association of support group attendance with quality of life metrics in head and neck cancer patients. Kyohei Itamura, Keck School of Medicine of USC, Los Angeles, CA, USA.

A30 Association of pretreatment BMI with risk of head and neck cancer: A large-scale single-center study. Anshu Khanna, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

A31 Deregulation of NOTCH 1/NR4A2 signaling axis in head and neck cancer pathogenesis. Muzafar Macha, University of Nebraska Medical Center, Omaha, NE, USA.

A32 Postoperative analgesia in a Ugandan population. Jason Thuener, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

A33 Fungal beta-glucans, EphA2 and oral cancer: Preliminary observations. Jason Thuener, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

A34 Effect of microvesicles on metalloproteinases secretion by myoepithelial cells. Gabriel Rena, São Leopoldo Mandic Faculty of Medicine, Campinas, SP, Brazil.
A35 Diagnostic performance and timing of post-treatment 18F-FDG PET/CT for head and neck cancer surveillance: a meta-analysis of reported studies. Adam Dmytriw, University of Toronto, Toronto, ON, Canada.

A36 Impact of feeding tube use on swallowing-related quality of life and weight in oropharyngeal cancer. Nedeljko Jovanovic, Western University, London, ON, Canada.


A41 Molecular factors impacting oropharyngeal cancer prognosis. Alina Diaconesco, McGill, Montreal, QC, Canada.

A42 Total laryngopharyngoesophagectomy with gastric transposition for hypopharyngeal cancer: A tertiary care center experience. Prerit Rao, Kasturba Medical College, Manipal, Karnataka, India.
Poster Session B
Tuesday, April 30, 2019
12:25 p.m.–1:55 p.m.

B01 Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinoma. R. Bryan Bell, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.


B03 A Phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer. Chwee Ming Lim, National University of Singapore, Singapore, Singapore.

B04 Molecular correlates of the non-T cell-inflamed tumor microenvironment in head and neck squamous cell carcinoma. Riyue Bao, University of Chicago, Chicago, IL, USA.

B05 Tumor evolution and oxidative stress in recurrent human papillomavirus-mediated oropharyngeal squamous cell carcinoma. Richard Harbison, University of Washington, Seattle, WA, USA.

B06 Repositioning the FDA-approved antiviral drug Ribavirin as targeted therapy for nasopharyngeal carcinoma. Sakibul Huq, Johns Hopkins University, Baltimore, MD, USA.

B07 High-risk human papillomavirus association with oropharyngeal squamous cell carcinoma in Taiwan. Guadalupe Lorenzatti Hiles, University of Michigan, Ann Arbor, MI, USA.

B08 Overcoming cisplatin resistance in sinonasal undifferentiated carcinoma by inhibiting the TGFβ signaling pathway in vivo. Yoko Takahashi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B09 Inactivating the EGFR-Arf1 axis by HDAC-targeted therapy to suppress invasiveness of head and neck squamous cell carcinoma. Yong Teng, Augusta University, Augusta, GA, USA.

B10 Manipulating translesion synthesis proteins MAGE-A4 and RAD18 in a murine model of oral cancer. Bethany Wagner, University of North Carolina, Chapel Hill, NC, USA.
Poster Session B
Tuesday, April 30, 2019
12:25 p.m.–1:55 p.m.

B11 Antagonist of cIAP1/2 and XIAP induces immunogenic cell death and alters antigen processing machinery in preclinical head and neck cancer models. Wenda Ye, NIH, Bethesda, MD, USA.

B12 An oxidative phosphorylation inhibitor identifies a metabolic vulnerability in human papilloma virus positive oropharyngeal squamous cell carcinoma. Meng Gao, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B13 Utilizing metabolic reprogramming to regulate fibroblast phenotype and reduce radiation fibrosis. Xiao Zhao, University of Toronto, Toronto, ON, Canada.

B14 Variations in the proteasome activity are associated with human papilloma virus (HPV) gene expression and patient survival in HPV+ oropharyngeal tumors. Frederico Gleber-Netto, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B15 CRISPR/Cas9 genetic screen identifies novel therapeutic strategies for treating HRAS mutant HNSCC with farnesyltransferase inhibitors (FTIs). Sehrish Javaid, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA.

B16 Transcriptional addiction to YAP1 -the major driving force of oral cancer carcinogenesis and evolution-. Muneyuki Masuda, Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.

B17 Functional characterization of HPV-human fusion transcripts in oropharyngeal cancer. Lisa Pinatti, University of Michigan, Ann Arbor, MI, USA.

B18 Loss of caspase-8 renders head and neck squamous cell carcinomas susceptible to necroptosis. Burak Uzunparmak, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B19 Malnutrition evaluation in head and neck cancer patients: Practice patterns among otolaryngologists and radiation oncologists. Amarbir Gill, University of California Davis, Sacramento, CA, USA.

B20 Hypopharyngeal carcinoma management: 25-year experience from a tertiary care medical center in United States. Mary Roselin Nittala, University of Mississippi Medical Center, Jackson, MS, USA.
B21 Factors affecting outcomes in patients with squamous cell carcinoma of oropharynx. Mary Roselin Nittala, University of Mississippi Medical Center, Jackson, MS, USA.


B23 The role of bone marrow transplantation in patients with Fanconi anemia and head and neck squamous cell carcinoma receiving radiotherapy: An examination of the International Fanconi Anemia (IFAR) Registry. Ade Obayemi, New York Presbyterian Hospital Cornell, New York, NY, USA.

B24 A rationale for screening for thyroid malignancy in breast cancer patients. Edouard Oudin, University of Arkansas for Medical Sciences, Little Rock, AR, USA.


B26 Analysis and comparison of survival and functional outcomes in oropharyngeal squamous cell carcinoma patients within City of Hope Cancer Center sites. Rebecca Pharaon, City of Hope Cancer Center, Duarte, CA, USA.

B28 HPV-related oropharyngeal cancer: Knowledge and beliefs among staff at community-based HIV/AIDS service organizations (ASOs). Aditi Tomar, Texas A&M University, College Station, TX, USA.

B29 Intraoperative identification of critical vascular landmarks of the lateral oropharynx and tongue base using Transoral Robotic Ultrasound (TORUS). Varun Vendra, Stanford University, Stanford, CA, USA.

B30 Locoregional control in laryngeal and hypopharyngeal cancer patients treated with radiotherapy using direct gross tumor volume to planning target volume expansion. Matthew Witek, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, WI, USA.
B31 Delineation of sentinel lymph nodes in athymic nude mice by systemically administered ultra-pH-sensitive micelles shows fluorescence intensity in metastatic nodes. Zachary Bennett, UT Southwestern Medical Center, Dallas, TX, USA.

B32 Impact of cancer associated fibroblasts on head and neck cancer stem cells. Molly Heft Neal, University of Michigan, Ann Arbor, MI, USA.

B33 Discovering distinct immune environments defined by the states of single cells within tumor microenvironment. Xinghua Lu, University of Pittsburgh, Pittsburgh, PA, USA.

B34 TGF-β-rich tumor-derived exosomes promote a pro-angiogenic phenotype in HNSCC. Nils Ludwig, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

B35 Characterization of exosomes extracted from primary tumor samples of HPV+/- oropharyngeal cancer. Vivian WU, Henry Ford Cancer Institute, Detroit, MI, USA.

B36 Avoidance of “prophylactic” tracheostomy in free-flap reconstruction surgery of the head and neck: Implications for postoperative outcomes and patient quality of life. Hannah Kuhar, Rush University Medical Center, Chicago, IL, USA.

B37 Cytopathologic assessment of gloves and instruments after major head and neck surgery: Implications for intraoperative practices. Hannah Kuhar, Rush University Medical Center, Chicago, IL, USA.

B38 Identification of stage wise miRNAs signature as potential biomarker in head and neck squamous cell carcinoma. Sugandh Kumar, Institute of Life Sciences, Bhubaneswar, Odisha, India.


B40 Trends in lymph node yield for neck dissection and oral cavity carcinoma survival. Punam Patel, Temple University Hospital, Philadelphia, PA, USA.

B41 In vitro cytotoxicity and in vivo efficacy of a novel protein ULLB-0005 in oral cancer. Dhananjay Sathe, Unichem Laboratories Ltd, Goa, India.